Avodart Cost in Hawaii 2026: What You'll Actually Pay

How Much Does Avodart Actually Cost in Hawaii in 2026?

Brand-name Avodart carries a manufacturer list price of approximately $290 per month in Hawaii, but almost no cash-pay patient pays that figure. Generic dutasteride 0.5 mg capsules are widely available at Hawaii retail pharmacies for around $25 per month, a more than 90% reduction from the brand price. The spread between list price and actual cash cost is one of the largest in the men's health category.

Dutasteride is a dual 5-alpha reductase inhibitor. It blocks both type I and type II isoenzymes, suppressing dihydrotestosterone (DHT) by more than 90% at steady state, compared with roughly 70% for finasteride. That pharmacological difference is why some clinicians prefer dutasteride for patients who have not responded to finasteride, though the FDA has only approved dutasteride for BPH, not for androgenetic alopecia. The FDA prescribing information for Avodart confirms the 0.5 mg once-daily dosing regimen and the BPH indication.

Price variation across Hawaii islands can be meaningful. Pharmacy chains on Oahu, Maui, and the Big Island may quote slightly different cash prices depending on their wholesaler contracts, but the generic should be available at any licensed pharmacy. Calling ahead for the cash price or using a discount card can cut costs further.

At retail, the average cash-pay price for a 30-capsule supply of generic dutasteride across Hawaii pharmacies in 2026 is approximately $25. GoodRx and similar platforms have documented that prescription discount cards routinely bring generic 5-alpha reductase inhibitor costs below $30 in most U.S. markets, and Hawaii is consistent with that pattern.

Does Hawaii Medicaid (Med-QUEST) Cover Avodart or Generic Dutasteride?

Hawaii Med-QUEST does not cover Avodart or generic dutasteride for male pattern hair loss. Coverage for BPH is also restricted and subject to prior authorization requirements that many patients do not meet on the first submission.

Hawaii's Med-QUEST Division administers Medicaid through managed care organizations including Aloha Care, Kaiser Permanente, and 'Ohana Health Plan. Each MCO maintains its own formulary, but all currently classify dutasteride as non-covered or non-preferred for cosmetic or off-label indications. The American Urological Association's 2023 BPH guideline states that "5-alpha reductase inhibitors are recommended for men with bothersome lower urinary tract symptoms and enlarged prostate," yet formulary placement does not automatically follow clinical recommendations.

For patients who have BPH documented in their chart with prostate volume greater than 30 mL and a PSA above 1.5 ng/mL, a prior authorization request citing the AUA guideline criteria may succeed. Patients seeking dutasteride for hair loss should not expect Med-QUEST reimbursement and should plan for cash-pay or discount-card pricing.

Low-income patients in Hawaii who do not qualify for Medicaid may still access the GSK Patient Assistance Program (PAP). GSK's program provides Avodart at no cost or reduced cost for patients meeting income thresholds, generally at or below 400% of the federal poverty level. Eligibility details and enrollment forms are available through the manufacturer directly, and most telehealth providers in Hawaii can assist with PAP paperwork.

Is Compounded Dutasteride Legal in Hawaii?

Yes. Compounded dutasteride is legal in Hawaii when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Compounded versions are not FDA-approved finished drug products, but the 503A framework under the Drug Quality and Security Act (DQSA) of 2013 permits licensed pharmacies to compound dutasteride for individual patients when a prescriber determines a commercial product does not meet the patient's clinical needs.

The practical cost advantage is real. Compounded dutasteride from a licensed 503A pharmacy in Hawaii runs approximately $40 per month, compared with $25 for the generic capsule. That premium typically reflects custom formulations, such as topical solutions or different concentrations, that are not available as commercial generics. A patient who wants a topical dutasteride preparation for scalp application, for example, can only obtain it through compounding.

Topical dutasteride has attracted clinical interest for androgenetic alopecia because it may deliver high local DHT suppression with lower systemic absorption than the oral form. Eun et al. (2010, J Am Acad Dermatol, N=153) showed that topical dutasteride 0.02% applied to the scalp for 24 weeks significantly increased hair counts compared with placebo and finasteride, with a favorable tolerability profile. The full study is available at PubMed PMID 20691790.

Patients should verify that any compounding pharmacy serving them in Hawaii holds an active license from the Hawaii Pharmacy and Poisons Advisory Committee (PPAC) and is compliant with USP Chapter 795 (non-sterile compounding) standards. Pharmacies shipping into Hawaii from the mainland must also hold a Hawaii non-resident pharmacy permit.

Which Insurance Plans Cover Avodart in Hawaii?

Commercial insurance coverage for Avodart and generic dutasteride in Hawaii varies by plan and by indication.

For BPH: Most commercial plans in Hawaii (HMSA, Kaiser Permanente Hawaii, UHA, and mainland carriers offering Hawaii group coverage) include generic dutasteride on Tier 2 or Tier 3 of their formulary when prescribed for BPH. Tier 2 co-pays typically range from $15 to $45 per 30-day supply. Tier 3 co-pays can reach $60 to $90 without a manufacturer savings card.

For hair loss: Virtually no commercial plan covers dutasteride when prescribed off-label for androgenetic alopecia. The diagnosis on the prescription matters enormously. A prescription written for "hair loss" will be rejected; one written for BPH in a patient who also has BPH may be covered.

Medicare Part D coverage follows a similar pattern. Medicare plans are prohibited from covering drugs prescribed exclusively for cosmetic purposes. BPH-indicated dutasteride may appear on some Part D formularies, but patients should check their specific plan's formulary at the start of each plan year.

The GSK Avodart savings card reduces out-of-pocket cost to as low as $0 per month for commercially insured patients who are not enrolled in a government program (Medicaid, Medicare, TRICARE). Uninsured patients using the card pay a fixed co-pay. The card is not valid for Hawaii Med-QUEST beneficiaries.

What Is the Cheapest Way to Get Dutasteride in Hawaii?

For most Hawaii patients, generic dutasteride at a retail pharmacy with a discount card is the cheapest option, averaging approximately $25 per month. Here is a practical cost ladder from lowest to highest:

1. Generic dutasteride plus GoodRx or similar discount card: approximately $10 to $25 per month at major Hawaii chains.
2. Telehealth platform subscription (often includes dispensing): $20 to $45 per month all-in, depending on the platform.
3. Compounded dutasteride from a licensed 503A pharmacy: approximately $40 per month for oral capsules, higher for topical formulations.
4. Brand-name Avodart with GSK savings card (commercially insured, non-government pay): $0 to $30 per month depending on card terms.
5. Brand-name Avodart, cash pay, no card: approximately $290 per month. This option makes financial sense for almost no one.

Patients should compare the 90-day supply price as well. Many Hawaii pharmacies offer a 90-day generic supply for $60 to $70, reducing the per-month cost to approximately $20 to $23.

A Costco or Sam's Club pharmacy membership is not required to fill prescriptions at club pharmacies in most states, and both have locations on Oahu. Their generic drug pricing is frequently below mainstream retail chains by 15 to 30%.

Can I Get Avodart or Dutasteride via Telehealth in Hawaii?

Yes. Telehealth prescribing of dutasteride is legal in Hawaii. Hawaii enacted permanent telehealth parity legislation, and the state's medical board permits prescribing after a valid patient-provider relationship is established via synchronous video or, in some circumstances, asynchronous review.

The Ryan Haight Act requires that controlled substances be prescribed only after an in-person visit, but dutasteride is not a controlled substance. This means Hawaii prescribers can initiate a dutasteride prescription entirely through a telehealth visit, including platforms based outside Hawaii that hold Hawaii prescribing authority.

A typical telehealth encounter for dutasteride in Hawaii proceeds as follows. The patient completes an online intake form covering medical history, current medications, and symptoms. A licensed prescriber (MD, DO, or APRN with prescribing authority) reviews the intake and may request a PSA level if BPH is the indication, or photographs and a standardized hair-loss scale (e.g., the Norwood scale for men) if hair loss is the indication. The prescription is sent electronically to a pharmacy of the patient's choice or dispensed through the platform's affiliated pharmacy.

Telehealth platforms that serve Hawaii and offer dutasteride include national men's health services operating under Hawaii provider licenses. Pricing models vary: some charge a monthly subscription of $20 to $30 that includes the medication; others charge a visit fee plus the pharmacy cost separately.

Clinical Evidence Supporting Dutasteride for Hair Loss

Dutasteride's off-label use for androgenetic alopecia is backed by a meaningful body of Phase II and Phase III trial data, even though the FDA has not approved it for this indication in the United States (it is approved for hair loss in South Korea and Japan at 0.5 mg daily).

The key study most often cited is Eun et al. (2010, J Am Acad Dermatol, N=153), a 24-week randomized controlled trial comparing topical dutasteride concentrations against finasteride and placebo. Target area hair count increased significantly in the dutasteride arms compared with placebo (P<0.001), with the 0.02% concentration performing best. PubMed PMID 20691790.

A later network meta-analysis published in the Journal of the American Academy of Dermatology (Adil and Godwin, 2017) pooled data from 22 randomized controlled trials covering finasteride and dutasteride for androgenetic alopecia. Dutasteride 0.5 mg daily demonstrated greater hair count improvement than finasteride 1 mg daily in the indirect comparison, though head-to-head data remain limited. The analysis is indexed at PubMed PMID 28923402.

Sexual side effects, including reduced libido and erectile dysfunction, occur in 1 to 9% of patients in clinical trials. Dutasteride's long half-life of approximately 5 weeks means serum DHT suppression persists for months after discontinuation. Patients planning to father children should be counseled accordingly, as dutasteride is excreted in semen and can affect a pregnant partner's fetus. The FDA label for Avodart lists pregnancy category X.

The HealthRX clinical team uses a three-tier prescribing framework for Hawaii patients requesting dutasteride for androgenetic alopecia. Tier 1 applies to patients with Norwood Grade II to IV hair loss, no PSA elevation, and no contraindications: oral generic dutasteride 0.5 mg daily via telehealth, filled at a local Hawaii pharmacy for approximately $25 per month. Tier 2 applies to patients who prefer topical administration or who experienced systemic side effects on oral finasteride: compounded topical dutasteride 0.02% solution via a licensed 503A pharmacy, approximately $40 to $70 per month depending on formulation. Tier 3 applies to patients with concurrent BPH who may qualify for insurance coverage: oral dutasteride prescribed with a BPH diagnosis, submitted to the commercial insurer with prior authorization documentation per AUA 2023 guidelines.

PSA Monitoring and Safety Considerations in Hawaii

Dutasteride suppresses serum PSA by approximately 50% after 6 months of use. Any Hawaii clinician ordering a PSA on a patient taking dutasteride must double the measured value to estimate the patient's true PSA for prostate cancer screening purposes. Failure to account for this effect can mask a clinically significant PSA rise.

The Prostate Cancer Prevention Trial Risk Calculator (PCPTRC 2.0) and the AUA's PSA guidelines note that dutasteride's PSA effect is consistent and predictable after 3 to 6 months of therapy. A rising PSA on dutasteride, even within a normal absolute range, warrants urology referral. Hawaii has a smaller concentration of urology specialists per capita than mainland metros, so telehealth-initiated prescriptions should include explicit instructions for the patient's primary care provider regarding PSA interpretation.

Patients with liver disease should use dutasteride with caution. The drug is metabolized via CYP3A4, and Hawaii's population includes groups with higher rates of hepatitis B carriage (particularly Asian and Pacific Islander communities), which can affect hepatic drug metabolism. A baseline liver function panel is appropriate for patients with any history of liver disease.

Hawaii-Specific Access Considerations

Hawaii's geographic isolation creates a few practical access issues that mainland patients do not face.

Pharmacy density is lower on neighbor islands. Patients on Molokai, Lanai, and parts of the Big Island may have limited local pharmacy options, making mail-order or telehealth-dispensed prescriptions especially valuable. The U.S. Postal Service and major carriers deliver to all Hawaii ZIP codes, so mail-order 90-day supplies are feasible for patients with stable regimens.

Hawaii's time zone (HST, UTC-10) means that mainland telehealth platforms may have limited synchronous appointment availability during Hawaii business hours. Asynchronous platforms that use questionnaire-based prescribing are more convenient for many Hawaii patients.

The state's high cost of living does not uniformly translate to higher drug prices for generics, because pharmacy reimbursement contracts are largely national. Generic dutasteride at $25 per month is consistent with or slightly below mainland averages according to 2026 discount card pricing databases.

Native Hawaiian and Pacific Islander populations carry higher rates of metabolic syndrome and prostate disease than the general U.S. population, per CDC data on health disparities. This makes BPH a clinically relevant condition in Hawaii's demographic profile, and access to affordable 5-alpha reductase inhibitor therapy carries real public health implications. CDC health disparities data documents these patterns.